United Therapeutics director granted 760 RSUs

Tracey Kevin reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Tracey Kevin reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Kevin Tracey reported an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU represents the right to receive, following vesting, one share of United Therapeutics common stock.

The RSUs become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, Tracey directly holds 760 RSUs, and the units have no stated expiration date.

Insider Trade Summary

Grant/Award: 760 shares

Grant/Award 1 txn

Insider Tracey Kevin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2, F3, F4	760	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 760 contracts (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. F2. Annual non-employee director award.
3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. F4. Not applicable as restricted stock units do not have an expiration date.

Key Figures

RSUs granted: 760.0000 units Underlying common shares: 760.0000 shares Total RSUs after grant: 760.0000 units +2 more

5 metrics

RSUs granted 760.0000 units Annual non-employee director award granted on 2026-07-22

Underlying common shares 760.0000 shares Each restricted stock unit represents one share of common stock

Total RSUs after grant 760.0000 units Director’s direct holdings following the reported award

Anticipated full vesting date June 25, 2027 Anticipated date of the next Annual Meeting of Shareholders

RSU grant price 0.0000 per share No cash price paid for the restricted stock unit award

Key Terms

Restricted Stock Unit, Annual non-employee director award, vesting, Annual Meeting of Shareholders

4 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the right to receive, following vesting, one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual non-employee director award financial

"Annual non-employee director award."

vesting financial

"represents the right to receive, following vesting, one share of common stock"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Shareholders regulatory

"the date of the next Annual Meeting of Shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did United Therapeutics (UTHR) director Kevin Tracey report?

Kevin Tracey reported receiving an annual non-employee director award of 760 restricted stock units (RSUs). Each RSU entitles him to receive one share of United Therapeutics common stock after the units vest under the company’s standard director vesting schedule.

How many restricted stock units did the UTHR director receive in this Form 4 filing?

The director received 760 restricted stock units. These RSUs are a form of equity compensation that will convert into 760 shares of United Therapeutics common stock once vesting conditions are met, aligning the director’s interests with long-term shareholder value.

What are the vesting terms for the 760 RSUs reported by United Therapeutics (UTHR)?

The 760 RSUs vest fully on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders. The next meeting is anticipated on June 25, 2027, at which point the award is expected to be fully vested.

How many United Therapeutics (UTHR) RSUs does the director hold after this transaction?

After the reported grant, the director holds 760 restricted stock units directly. Each unit corresponds to one potential share of United Therapeutics common stock, deliverable following vesting, and the RSUs do not carry an expiration date.

Does the United Therapeutics (UTHR) director pay a price per share for the 760 RSUs?

No cash price is paid; the reported transaction price is $0.0000 per RSU. The award is part of the director’s compensation, granting the right to receive common shares upon vesting rather than being a market purchase of stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:45 PM Accepted by SEC EDGAR 07/23/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tracey Kevin

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/22/2026		A		760(2)		06/25/2027(3)	(4)	Common Stock	760	$0.00	760	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Annual non-employee director award.

3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

4. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)